Literature DB >> 8127398

Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat.

J Weidenfeld1, S Feldman, R Mechoulam.   

Abstract

Anandamide (arachidonylethanolamide), an endogenous ligand of the cannabinoid receptor, was recently isolated from porcine brain. We report here for the first time on the effect of this ligand on the hypothalamo-pituitary adrenal (HPA) axis in comparison to that of the plant cannabinoid delta 9-tetrahydrocannabinol (THC). Intracerebroventricular injection of anandamide or THC (50 or 150 micrograms/rat) increased significantly the serum levels of ACTH and corticosterone in a dose-dependent manner and caused a pronounced depletion of CRF-41 in the median eminence. These data suggest that anandamide parallels THC in activating the HPA axis via mediation of a central mechanism which involves the secretion of CRF-41.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8127398     DOI: 10.1159/000126646

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  27 in total

1.  Gene-environment interplay in affect and dementia: emotional modulation of cognitive expression in personal outcomes.

Authors:  T Palomo; R J Beninger; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 2.  Substance use modulates stress reactivity: Behavioral and physiological outcomes.

Authors:  Anne Q Fosnocht; Lisa A Briand
Journal:  Physiol Behav       Date:  2016-02-19

3.  Corticosteroid dependent and independent effects of a cannabinoid agonist on core temperature, motor activity, and prepulse inhibition of the acoustic startle reflex in Wistar rats.

Authors:  Avdesh Avdesh; Vincent Cornelisse; Mathew Thomas Martin-Iverson
Journal:  Psychopharmacology (Berl)       Date:  2011-09-27       Impact factor: 4.530

4.  Absence of delta -9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice.

Authors:  A Zimmer; E Valjent; M Konig; A M Zimmer; P Robledo; H Hahn; O Valverde; R Maldonado
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

5.  Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction.

Authors:  M Mas-Nieto; B Pommier; E T Tzavara; A Caneparo; S Da Nascimento; G Le Fur; B P Roques; F Noble
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

6.  Decreased cannabinoid CB1 receptor mRNA levels and immunoreactivity in pituitary hyperplasia induced by prolonged exposure to estrogens.

Authors:  S González; G Mauriello-Romanazzi; F Berrendero; J A Ramos; M F Franzoni; J Fernández-Ruiz
Journal:  Pituitary       Date:  2000-12       Impact factor: 4.107

Review 7.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 8.  Role of endocannabinoid system in mental diseases.

Authors:  Jorge Manzanares; Leyre Urigüen; Gabriel Rubio; Tomás Palomo
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

9.  Cannabinoids modulate ultrasound-induced aversive responses in rats.

Authors:  David P Finn; Maulik D Jhaveri; Simon R G Beckett; David A Kendall; Charles A Marsden; Victoria Chapman
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

10.  Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212.

Authors:  J Ludovic Croxford; Stephen D Miller
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.